How Risky Is Too Risky?
This article was originally published in RPM Report
Executive Summary
Would a Big Pharma company ever sell a product like Tysabri?
You may also be interested in...
Regulatory Risk and Business Development: Type 2 Diabetes Falls Out of Favor
It's a buyer's market for type 2 diabetes drugs, and you can thank FDA for that. At least, that is the sentiment of business development executives from Big Pharma. Transaction data in 2008 back up that view.
Change of Control: Why Getting it Right Matters Even More
Private biotechs' growing dependence on an M&A exit and the more lively acquisition activity throughout the sector means change of control provisions are being far more heavily negotiated than in the past, and it's critical to understand how far-reaching these provisions could be for biotechs hoping for successful exits.
US FDA Alzheimer Guidance Update Reflects Changes In Biomarkers – And Leadership
Latest update to draft guidance on early Alzheimer’s drug development is the third iteration of a document first published in 2013. The history of the guidance is a reflection of structural and leadership changes in the neurology review team at FDA.